GE Healthcare Announces Moves to Bolster Supply of Iodinated Contrast Media for CT and X-Ray Imaging
A multi-year agreement with a large Chile-based supplier of raw iodine is part of GE Healthcare’s commitment to increase the production of iodinated contrast media, commonly used in computed tomography imaging, by 30 million annually in 2025.
In a move to fortify the supply of iodinated contrast media (ICM) for computed tomography (CT) and X-ray imaging, GE Healthcare has entered into a multi-year partnership with Sociedad Quimica y Minera de Chile S.A. (SQM), a mining company in Chile, to secure and increase the supply of raw iodine material, a core ingredient for ICM.
Reportedly one of the largest worldwide producers of iodine, SQM said approximately 24 percent of its iodine production is utilized for ICM in medical imaging. The agreement between GE Healthcare and SQM calls for annual increases of iodine supply. This is part of a commitment from GE Healthcare to increase the production of ICM patient doses by 30 million annually by 2025, according to the company.
(Editor’s note: For related content, see “Can EHR Interventions Have an Impact in Conserving Iodinated Contrast Media in Radiology?,” “Iodinated Contrast Media Shortage: Practical Solutions and Applications in Radiology” and “Lessons Learned from the Iodinated Contrast Media Shortage: A Neuroradiologist’s Perspective.”)
GE Healthcare also announced a $30 million investment in a new manufacturing line at its contrast media production facility in Cork, Ireland.
“We expect global demand for iodinated contrast media to double in the next 10 years,” noted Kevin O’Neill, the president and CEO of GE Healthcare Pharmaceutical Diagnostics. “As an industry leader, we understand our responsibility to help meet this growing demand from customers and patients by investing in production capacity and securing higher volumes of iodine raw material.”
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.
